Future growth expectations in earnings/operating earnings/profits/EPS?

Earnings growth expected to continue, supported by steady volume growth across business segments. EBITDA margins are projected to remain around 12%-13% in the near term, with potential improvement to ~15% upon B2C portfolio optimization and new product contributions. Operating leverage from new capacities (Dahej, Unitop) expected to ramp up over approximately two years, reaching optimal utilization by FY27, supporting margin expansion. New product developments and bio-surfactants approvals anticipate higher-margin sales contributing positively from next year. Export growth, currently at ~30% o

Any current/future new fundraising through debt or equity?

The company’s ongoing capacity expansion investments are being funded through a mix of internal accruals and debt. For the proposed greenfield specialty chemicals manufacturing facility in Saudi Arabia (KSA), the project is planned to be funded through a prudent mix of equity, debt, and internal accruals, while also exploring available regional incentives. An initial equity infusion approval of roughly $8 million has been taken to start evaluation for the KSA facility; this amount is not the total CAPEX. Formal board approval and detailed evaluation are awaited for the full capex amount relate

Any current/future capex/capital investment/strategic investment?

Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26. Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26. The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval. Most capacity enhancement CAPEX for FY26 largely capitalized (~Rs. 200 crore group-wide); future C

Future growth expectations in sales/revenue/volumes?

Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Domestic demand, especially in textiles, remains soft but export markets like Southeast Asia, MENA, Middle East, and Turkey show promise. Animal Health and Nutrition (AHN) business demonstrated strong growth; expected to maintain average growth with new premix plant coming onstream. Ramp-up of new capacities at Dahej and Unitop to continue, with optimal utilization targeted by FY27, supporting volume growth. New product development and market expansion prioritiz

IN US

Sale is live|00:00:00left today

Rossari Biotech LtdQ4 FY27Chemicals & Petrochemicals

Rossari Biotech Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹535P/E: 18.8Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26.
→Domestic demand, especially in textiles, remains soft but export markets like Southeast Asia, MENA, Middle East, and Turkey show promise.
→Animal Health and Nutrition (AHN) business demonstrated strong growth; expected to maintain average growth with new premix plant coming onstream.
→Ramp-up of new capacities at Dahej and Unitop to continue, with optimal utilization targeted by FY27, supporting volume growth.
→New product development and market expansion prioritized, including setting up a manufacturing facility in KSA to enhance supply chain and export reach.
→Premix plant for AHN anticipated to contribute volumes from Q4 FY26 onwards and next year.
→Overall focus on driving sales through key accounts, geographic expansion, and new product introductions for sustainable growth.

Margin guidance

Category 3

→Earnings growth expected to continue, supported by steady volume growth across business segments.
→EBITDA margins are projected to remain around 12%-13% in the near term, with potential improvement to ~15% upon B2C portfolio optimization and new product contributions.
→Operating leverage from new capacities (Dahej, Unitop) expected to ramp up over approximately two years, reaching optimal utilization by FY27, supporting margin expansion.
→New product developments and bio-surfactants approvals anticipate higher-margin sales contributing positively from next year.
→Export growth, currently at ~30% of turnover, expected to grow faster than domestic, driving overall revenue.
→Domestic demand remains muted but is a long-term focus for growth initiatives.
→Capex largely completed; future investments will target product development and R&D, enhancing profitability.
→EPS expected to improve in line with margin expansion and revenue growth from product mix and export expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company’s ongoing capacity expansion investments are being funded through a mix of internal accruals and debt.
→For the proposed greenfield specialty chemicals manufacturing facility in Saudi Arabia (KSA), the project is planned to be funded through a prudent mix of equity, debt, and internal accruals, while also exploring available regional incentives.
→An initial equity infusion approval of roughly $8 million has been taken to start evaluation for the KSA facility; this amount is not the total CAPEX.
→Formal board approval and detailed evaluation are awaited for the full capex amount related to the KSA project.
→There is no mention of any immediate new fundraising exclusively through equity or debt beyond these planned and ongoing funding sources.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Rossari Biotech Limited. However, some relevant points related to demand and order outlook include: - Exports have been growing strongly and contributed about 30% of turnover in the 9 months ended FY26. - Domestic demand, especially in textiles, has been soft but showed some signs of recovery in Q3 FY26. - The company is adding customers in new geographies like Turkey, Uzbekistan, Morocco, Southeast Asia, and others, indicating an expanding order pipeline. - Discussions and in-principle approvals for a new greenfield manufacturing facility in Saudi Arabia are underway, aimed at strategically catering to regional and export demand. - Ramp-up of new capacities at Dahej and Unitop is expected to progressively contribute to order fulfillment over the next 2 years. - The Animal Health and Nutrition (AHN) segment saw strong growth and new market additions. - Overall, order inflows are supported by diversification and export market expansion, with expectations of better demand outlook in Q4 and beyond.

Capex plans

Yes

→Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.
→Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26.
→The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval.
→Most capacity enhancement CAPEX for FY26 largely capitalized (~Rs. 200 crore group-wide); future CAPEX over next 2-3 years will focus on new product development, piloting, and R&D rather than capacity expansion.
→The company plans prudent funding of CAPEX through a mix of internal accruals, debt, and exploring regional incentives for KSA project.

How does Rossari Biotech Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Rossari Biotech Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Rossari Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio